
    
      This is an open label, multi-center, randomized control study comparing the combination of
      sintilimab and anlotinib with standard platinum-based chemotherapy in treat-na√Øve advanced
      (unresectable stage IIIB, IIIC and IV patients without driven-gene mutations) NSCLC patients.
      Eligible subjects are 1:1 randomized into the experimental group (sintilimab combined with
      anlotinib) or the control group (standard platinum-based chemotherapy).
    
  